AstraZeneca’s Brilinta Fails to Win FDA Approval
by Melly Alazraki on Dec.17, 2010, under Towing
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.
Continue reading AstraZeneca’s Brilinta Fails to Win FDA Approval
AstraZeneca’s Brilinta Fails to Win FDA Approval originally appeared on DailyFinance on Fri, 17 Dec 2010 08:08:00.
Filed Under: Company News, Health Care, Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Astrazeneca, Stocks in the News



